Automated cell therapy manufacturing MoU
Filed with ASX · · 4 pages · English
Summary by 6ix AI
AdAlta Ltd. has announced a Memorandum of Understanding with Oribiotech and Cell Therapies to enhance cell therapy manufacturing capabilities in the Asia Pacific region. The collaboration aims to deploy Oribiotech's automated manufacturing platform, IRO, to improve the efficiency and cost-effectiveness of CAR-T therapies. This initiative supports AdAlta's strategy to deliver scalable cell therapies for solid cancers and positions the company as a leader in advanced manufacturing. The IRO platform is designed to address key challenges in cell therapy production, including high costs and slow manufacturing times.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from AdAlta
- BZDS1901 clinical update
- AdCella and SHcell hold first JDC meeting
- New AD-214 patent granted
- AdCella expands clinical advisory board
- AdCella Clinical Advisory Board convened
Later from AdAlta
- BZDS1901 manufacturing agreement
- $2.5m placement
- Regulatory advisors appointed for BZDS1901
- Second BZDS1901 milestone paid
- Oktopi AI collaboration for research efficiency
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta